RA Capital Sells $372K in Werewolf Therapeutics Shares, Reducing Stake Amid Strategic Review
HOWL is trading near its 52-week low of $0.355 (12% above the low).
Summary
RA Capital Management and its affiliates sold approximately $372,000 worth of Werewolf Therapeutics shares between June 9 and June 15, 2026, reducing their beneficial ownership to 10.6%.
Key Events · Ownership and Investor Activity · HOWL
-
Significant Share Sales
RA Capital Management, L.P. and its affiliated funds sold a total of 977,437 shares of Werewolf Therapeutics common stock in open market transactions between June 9 and June 15, 2026.
-
Total Transaction Value
The aggregate value of these sales amounted to approximately $371,965, with an average price per share ranging from $0.37 to $0.40.
-
Reduced Ownership Stake
Following these transactions, the reporting persons' beneficial ownership in Werewolf Therapeutics stands at 5,138,703 shares, representing 10.6% of the outstanding common stock.
-
Continuation of Institutional Distribution
This filing marks a continuation of institutional investors reducing their positions, aligning with a broader pattern of distribution observed in recent filings and insider activity.
Analysis · HOWL · Life Sciences
RA Capital Management, a significant institutional investor, has continued to reduce its stake in Werewolf Therapeutics by selling approximately $372,000 worth of shares. This ongoing distribution by a major shareholder, following previous sales by other institutional investors, adds to negative sentiment, especially as the company is exploring strategic alternatives and faces a 'going concern' warning. The sales occurred at prices ranging from $0.37 to $0.40 per share, close to the current market price.
At the time of this filing, HOWL was trading at $0.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.9M. The 52-week trading range was $0.36 to $2.38. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.